Ind-Swift Laboratories Limited moves to reshape its capital structure

The stated object of the issue is to use the warrant proceeds for:

• Expansion of existing manufacturing facilities and warehouse infrastructure
• Future product-development initiatives ^[1]

This is therefore framed as growth and capacity investment, not as a specifically disclosed debt-repayment or working-capital-raising exercise.

Alignment with the latest balance sheet

The latest balance-sheet snapshot is Q4 FY26:

• Total debt was Rs 17.91 Crores, comprising Rs 5.61 Crores of current borrowings and Rs 12.30 Crores of non-current borrowings ^{[2] [3] [4]}.
• Cash and equivalents were Rs 429.85 Crores, while reported net debt was negative Rs 411.94 Crores, indicating a net-cash position ^{[5] [6]}.
• Liquidity was strong on reported balance-sheet metrics: current assets were Rs 976.75 Crores, current liabilities Rs 254.70 Crores, and the current ratio 3.83x ^{[7] [8] [9]}.
• Working capital remains material: inventories were Rs 147.93 Crores, trade receivables Rs 198.55 Crores, and trade payables Rs 145.86 Crores ^{[10] [11] [12]}.

Assessment: the capital infusion does not appear necessary to meet an immediate debt-servicing or liquidity shortfall. The company had cash substantially above reported borrowings and a sizeable current-asset buffer. It is more logically aligned with funding the disclosed manufacturing, warehouse and product-development expansion. That said, the balance sheet shows a meaningful working-capital base, so the proceeds could also provide flexibility for incremental inventory and receivables as capacity scales. The disclosure does not separately earmark the proceeds between expansion, product development, debt repayment and working capital.

The warrant announcement separately refers to an exercise price of Rs 147 per warrant and an exercise period of up to 18 months; the cited announcement also refers to Rs 343 million, or Rs 34.3 Crores, of proceeds at an issue price of Rs 49 ^[13]. The timing and amount of any later balance received on conversion should therefore be distinguished from the initial warrant-issue proceeds.

Issue price: Ind-Swift Laboratories fixed the preferential issue price at Rs 196 per warrant. The cited regulatory floor was Rs 195.98, described as based on the 10-day VWAP, making the issue price Rs 0.02, or approximately 0.01%, above that floor. ^[14]

Comparison with the requested benchmarks:

• 90-day VWAP: A 90-day VWAP is not reported in the cited evidence, so an exact comparison against that benchmark cannot be made. The available disclosure refers to a 10-day VWAP, not a 90-day VWAP. ^[14]
• Book value per share: The latest quarterly figure available is Rs 15.94 per share on a consolidated basis for Q1 FY27. ^[15]
• Issue price versus book value: Rs 196 is Rs 180.06 above book value, or approximately 12.30x the reported book value (derived from Rs 196 / Rs 15.94).

Read-through: The warrant price was set essentially at the cited regulatory floor, but at a substantial premium to the latest reported accounting book value.

Upon full conversion, the promoter group’s potential shareholding would be 47.18% of the fully diluted voting capital. This comprises 44,334,278 shares—37,334,278 existing promoter/PAC shares plus 7,000,000 shares from the warrants—out of diluted capital of 93,961,558 shares. ^[16]

• Impact: versus the pre-issue promoter/PAC holding of 43.06%, the fully diluted stake increases by approximately 4.12 percentage points. ^{[17] [16]}
• The warrants themselves represent 7.45% of the fully diluted share capital. Before conversion, they do not form part of the promoter group’s ordinary voting-share holding; the filing reports the promoter/PAC group at 42.93% of the post-allotment voting capital and 47.18% on a fully diluted basis. ^[16]

Conversion timeline

The 7,000,000 warrants were allotted to Essix Biosciences Limited, a promoter-group entity, on 17 September 2026. ^[18]

Under the issue terms, each warrant is convertible into one equity share within 18 months from the date of allotment. ^[19] Accordingly, the conversion window runs from 17 September 2026 to approximately 17 March 2028, subject to the company’s conversion intimation and allotment process. The filing evidence specifies the 18-month exercise period but does not provide an earlier tranche-wise conversion schedule.